Geode Capital Management LLC Purchases 12,750 Shares of LivaNova PLC $LIVN

Geode Capital Management LLC boosted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,458,838 shares of the company’s stock after buying an additional 12,750 shares during the period. Geode Capital Management LLC owned approximately 2.67% of LivaNova worth $89,775,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. increased its position in LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after buying an additional 267 shares in the last quarter. State of Wyoming bought a new position in LivaNova during the 2nd quarter valued at approximately $31,000. Quarry LP bought a new position in LivaNova during the 3rd quarter valued at approximately $36,000. EverSource Wealth Advisors LLC increased its position in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares in the last quarter. Finally, Covestor Ltd increased its position in LivaNova by 108.6% during the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after buying an additional 392 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Needham & Company LLC raised their price objective on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Mizuho raised their price objective on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Robert W. Baird reduced their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Barclays raised their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a research report on Thursday, February 19th. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, LivaNova has an average rating of “Moderate Buy” and an average price target of $79.38.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares in the company, valued at approximately $547,521. This trade represents a 19.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.35% of the company’s stock.

LivaNova Stock Performance

Shares of LIVN opened at $72.36 on Monday. The business’s fifty day simple moving average is $67.58 and its two-hundred day simple moving average is $65.02. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. LivaNova PLC has a 12 month low of $41.01 and a 12 month high of $75.82. The company has a market cap of $3.97 billion, a price-to-earnings ratio of 37.11 and a beta of 0.88.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. During the same period last year, the business posted $0.88 EPS. The company’s revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Research analysts anticipate that LivaNova PLC will post 3.72 earnings per share for the current fiscal year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.